New drug combo targets Hard-to-Treat breast cancer

NCT ID NCT06099769

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for people with advanced breast cancer that is androgen receptor-positive (AR+) and either triple-negative or low in estrogen receptors. It tests whether the drug enzalutamide, alone or combined with mifepristone, can control the cancer as well as standard chemotherapy. About 201 participants will be randomly assigned to one of three treatment groups to compare how long the cancer stays under control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANDROGEN RECEPTOR-POSITIVE METASTATIC TRIPLE-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC BREAST CANCER

Contacts and locations

Locations

Dana Farber Cancer Institute (Data Collection Only)
RECRUITING

Boston, Massachusetts, 02115, United States
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
RECRUITING

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
RECRUITING

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (All Protocol Activities)
RECRUITING

Harrison, New York, 10604, United States
University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35294, United States
University of California San Francisco (Data collection only)
RECRUITING

San Francisco, California, 94143, United States
University of Chicago Medical Center
RECRUITING

Chicago, Illinois, 60637, United States
University of North Carolina
RECRUITING

Chapel Hill, North Carolina, 27514, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.